In a major breakthrough for Russia’s Sputnik V Covid-19 vaccine, the prestigious British medical journal The Lancet has published preliminary Phase III trial results showing it is highly effective – notably, for all age groups. Data from 19,866 volunteers – 4,902 of whom were in the placebo group – showed that Sputnik V had an overall efficacy of 91.6 percent, rising to 91.8 percent among the group of 2,144 volunteers over the age of 60, according to the interim results of the Phase III clinical trial published in the Lancet on Tuesday.
At the end of the study, there were 62 confirmed Covid-19 cases in the placebo group and only 16 in the vaccine group. Sputnik V proved to be 100 percent effective in preventing the development of severe cases.